Regeneron Pharmaceuticals has demonstrated that its gene therapy, DB-OTO, can restore hearing in children born with profound deafness due to OTOF gene mutations. The therapy uses a dual-vector viral system to deliver functional genes to the inner ear, allowing patients to achieve normal hearing levels within months.
TLDR: Regeneron’s DB-OTO gene therapy successfully restored hearing in children with OTOF-related deafness during a Phase 1/2 trial. By delivering a working gene to the cochlea via a dual-vector system, the treatment enabled an 11-month-old patient to reach normal hearing thresholds, marking a major advance in biological hearing restoration.
Regeneron Pharmaceuticals recently reported significant clinical progress in treating a rare form of hereditary deafness. The breakthrough involves a gene therapy known as DB-OTO, which targets mutations in the OTOF gene. This specific genetic defect prevents the production of otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. Without this protein, the auditory hair cells cannot communicate with the auditory nerve, resulting in profound sensorineural hearing loss from birth.
The clinical data stems from the ongoing Phase 1/2 CHORD trial, which evaluates the safety and efficacy of the therapy in pediatric patients. One of the most notable cases involved an infant treated before the age of one. Following a single intracochlear injection of the gene therapy, the patient demonstrated a rapid improvement in auditory responses. Within six months, clinical assessments confirmed that the child’s hearing had reached levels within the normal range, as measured by auditory brainstem response testing.
DB-OTO utilizes a modified adeno-associated virus (AAV) to deliver a functional copy of the OTOF gene directly to the cochlea. Because the OTOF gene is too large to fit into a single standard AAV vector, researchers employed a dual-vector approach. This technique involves splitting the gene into two parts, each carried by a separate viral shell, which then recombine within the target inner hair cells to form the full-length protein. This delivery mechanism is designed to be cell-specific, ensuring that the otoferlin protein is expressed only where it is naturally required.
By restoring the cellular machinery necessary for sound transduction, the therapy bypasses the need for traditional interventions like cochlear implants. While implants provide electrical stimulation to the nerve, gene therapy aims to restore the ear’s natural biological function. The success of this trial represents a milestone in the field of otology and genetic medicine. While cochlear implants have long been the standard of care for profound deafness, they do not restore the natural nuances of sound or the biological complexity of the ear.
Gene therapy offers a potential permanent solution by addressing the underlying cause of the sensory deficit. Researchers emphasized that the timing of the intervention is critical, as the brain’s auditory processing centers require early stimulation to develop correctly during the first years of life. Safety remains a primary focus of the CHORD trial. To date, the procedure has been well-tolerated by the participants, with no serious adverse events linked to the therapy itself. The surgical delivery method involves a specialized injection into the cochlea, performed under general anesthesia.
This precision approach minimizes systemic exposure to the viral vector, reducing the risk of immune reactions outside the target area. The surgical team uses advanced imaging to ensure the vector reaches the perilymph, the fluid surrounding the inner hair cells. The implications of this research extend beyond the OTOF gene. Regeneron and its subsidiary, Decibel Therapeutics, are exploring similar platforms for other forms of monogenic hearing loss.
As genetic screening for newborns becomes more comprehensive, the ability to identify and treat these conditions in infancy could fundamentally change the trajectory of pediatric healthcare. Future studies will continue to monitor the long-term durability of the hearing restoration and expand the trial to include older children to determine the upper age limit for effective treatment. This work paves the way for a new era of regenerative medicine where sensory deficits are corrected at the molecular level, potentially eliminating the need for lifelong prosthetic reliance.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.